


Form PTO-1449 (modified)

List of Patents and Publications for Applicant

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

MYOG:044US

Serial No.

10/848,820

Applicant

Timothy A. McKinsey *et al.*

Filing Date:

May 19, 2004

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CP	A1	4,196,265	04/01/80	Koprowski <i>et al.</i>	435	70.21	08/11/78
CP	A2	4,458,066	07/03/84	Caruthers <i>et al.</i>	536	25.34	03/24/81
CP	A3	4,415,723	11/15/83	Hedges <i>et al.</i>	528	204	03/19/82
CP	A4	4,873,191	10/10/89	Wagner <i>et al.</i>	800	25	08/18/86
CP	A5	5,354,855	10/11/94	Cech <i>et al.</i>	536	24.1	02/28/92
CP	A6	5,604,251	02/18/97	Heitsch <i>et al.</i>	514	396	06/07/95
CP	A7	5,795,715	08/18/98	Livache <i>et al.</i>	435	6	06/17/94
CP	A8	5,889,136	03/30/99	Scaringe <i>et al.</i>	536	25.34	06/09/95
CP	A9	5,955,501	09/21/99	Driedger <i>et al.</i>	514	533	06/07/95
CP	A10	6,043,270	03/28/00	Driedger <i>et al.</i>	514	450	06/07/95
CP	A11	6,080,784	06/27/00	Driedger <i>et al.</i>	514	546	06/07/95
CP	A12	6,441,020	08/27/02	Quick <i>et al.</i>	514	411	09/28/98
CP	A13	6,528,294	03/04/03	Li <i>et al.</i>	435	194	02/01/02

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CP	B1	WO 01/68836	09/20/01	WIPO			English
CP	B2	WO 01/36646	05/25/01	WIPO			English
CP	B3	WO 00/44914	08/03/00	WIPO			English
CP	B4	WO 99/32619	07/01/99	WIPO			English
CP	B5	WO 84/03564	09/13/84	WIPO			English

25435187.1

EXAMINER: /Clark Petersen/

DATE CONSIDERED: 02/26/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. MYOG:044US	Serial No. 10/848,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Timothy A. McKinsey <i>et al.</i>	
		Filing Date: May 19, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CP	C1	Butler <i>et al.</i> , "Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo," <i>Cancer Res.</i> , 60:5165-5170, 2000.
CP	C2	Caplen <i>et al.</i> , "dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference," <i>Gene</i> , 252(1-2):95-105, 2000.
CP	C3	Coffey <i>et al.</i> , "The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid," <i>Cancer Res.</i> , 61:3591-3594, 2001.
CP	C4	Eichhorn and Bristow, "Medical therapy can improve the biological properties of the chronically failing heart," <i>Circulation</i> , 94:2285-2296, 1996.
CP	C5	Gao, <i>et al.</i> , "Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase," <i>J. Biol. Chem.</i> , 15:8675-81, 1996.
CP	C6	Grishok <i>et al.</i> , "Genetic requirements for inheritance of RNAi in <i>C. elegans</i> ," <i>Science</i> , 287:2494-2497, 2000.
CP	C7	Harlow and Lane, <i>Using Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, 1988.
CP	C8	Haworth <i>et al.</i> , "Expression and activity of protein kinase D/protein kinase C mu in myocardium: evidence for alpha1-adrenergic receptor- and protein kinase C-mediated regulation," <i>J. Mol. Cell. Cardiol.</i> , 32:1013-1023, 2000.
CP	C9	Hayashi <i>et al.</i> , "PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu," <i>Biochim. Biophys. Acta</i> , 1450:99-106, 1999.
CP	C10	Isselbacher <i>et al.</i> , <i>Harrison's Principles of Internal Medicine</i> , McGraw-Hill, NY, 416-431, 1994.
CP	C11	Johannes <i>et al.</i> , "PKCu is a novel, atypical member of the protein kinase C family," <i>J. Biol. Chem.</i> , 269(8):6140-8, 1994.
CP	C12	Katoh <i>et al.</i> , "MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression," <i>J. Biol. Chem.</i> , 273:1511-18, 1998.
CP	C13	Lu <i>et al.</i> , "Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases," <i>Proc. Natl. Acad. Sci. USA</i> , 97:4070-4075, 2000.

25435187.1

EXAMINER: /Clark Petersen/

DATE CONSIDERED: 02/26/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. MYOG:044US	Serial No. 10/848,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Timothy A. McKinsey <i>et al.</i>	
		Filing Date: May 19, 2004	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 2	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CP	C14	Marks <i>et al.</i> , "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells," <i>J. Natl. Cancer Inst.</i> , 92(15):1210-1216, 2000.
CP	C15	McKinsey <i>et al.</i> , "Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5," <i>Proc. Natl. Acad. Sci. USA</i> , 97:14400-14405, 2000.
CP	C16	McKinsey <i>et al.</i> , "Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation," <i>Nature</i> , 408:106-111, 2000b.
CP	C17	Montgomery <i>et al.</i> , "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 95:15502-15507, 1998.
CP	C18	Nishikawa <i>et al.</i> , "Determination of the specific substrate sequence motifs of protein kinase C isozymes," <i>J. Biol. Chem.</i> , 276:3310-3318, 1997.
CP	C19	Sturany <i>et al.</i> , "Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases," <i>J. Biol. Chem.</i> , 276:3310-3318, 2001.
CP	C20	Taunton <i>et al.</i> , "A mammalian histone deacetylase related to the yeast transcriptional regulator rpd3p," <i>Science</i> , 272:408-411, 1996.
CP	C21	Tong <i>et al.</i> , "Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain," <i>Nucleic Acids Res.</i> , 30:1114-23, 2002.
CP	C22	Valverde <i>et al.</i> , "Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain," <i>Proc. Natl. Acad. Sci. USA</i> , 91(18):8572-6, 1994.
CP	C23	Van Lint <i>et al.</i> , "Protein kinase D: an intracellular traffic regulator on the move," <i>Trends in Cell. Biol.</i> , 12:193-200, 2002.
CP	C24	Van den Wyngaert <i>et al.</i> , "Cloning and characterization of human histone deacetylase 8," <i>FEBS Lett.</i> , 478:77-83, 2000.
CP	C25	Zhang <i>et al.</i> , "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy," <i>Cell</i> , 110:479-488, 2002.

25435187.1

EXAMINER: /Clark Petersen/	DATE CONSIDERED: 02/26/2007
----------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)	Atty. Docket No.: MYOG:044US	Serial No.: 10/848,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant: Timothy A. McKinsey <i>et al.</i>	
	Filing Date: May 19, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CP	A14	2003/0134774	07/17/03	Steinberg <i>et al.</i>	514	1	06/14/02
CP	A15	2003/0229030	12/11/03	Theoharides	514	27	06/11/02

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
CP	B6	EP 1297851	04/02/03	Europe	English
CP	B7	WO 03/075910	09/18/03	WIPO	English
CP	B8	WO 2004/014222	02/19/04	WIPO	English
CP	B9	WO 2004/017957	03/04/04	WIPO	English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CP	C26	Bristow and Gilbert, "Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure," <i>Eur. Heart J.</i> , 16:20-31, 1995.
CP	C27	Haider <i>et al.</i> , "Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells," <i>Molecular Pharmacology</i> , 62:772-777, 2002.
CP	C28	Thorburn and Thorburn, "The tyrosine kinase inhibitor, genistein, prevents alpha-adrenergic-induced cardiac muscle cell hypertrophy by inhibiting activation of the Ras-MAP kinase signaling pathway," <i>Biochemical and Biophysical Research Communications</i> , 202:1586-1591, 1994.
CP	C29	Xu <i>et al.</i> , "Stimulation of protein synthesis by phosphatidic acid in rat cardiomyocytes," <i>Biochemical Pharmacology</i> , 52:1735-1740, 1996.

25738710.1

EXAMINER: /Clark Petersen/	DATE CONSIDERED: 02/26/2007
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)